AZD8421

AZD8421 is a selective CDK2 inhibitor (IC50 = 9 nM) as well as achieving CDK family selectivity in cells versus key off-targets (CDK1, CDK4/6, CDK9), AZD8421 had no significant kinase inhibition outside the CDK family. AZD8421 inhibits cancer cell proliferation by inhibiting pRB phosphorylation, inducing cell cycle arrest in G1/S phase and senescence. AZD8421 can be studied in research for breast cancer and ovarian cancer[1].

Product Specifications

CAS Number

[3047321-53-6]

UNSPSC

12352005

Target

CDK

Type

Reference compound

Related Pathways

Cell Cycle/DNA Damage

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/azd8421.html

Concentration

10mM

Purity

99.60

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

CCN1C=NC2=C1N=C(N[C@@H](CC)[C@@H](C)O)N=C2N[C@@H]3CN(S(=O)(NCC)=O)CC3

Molecular Formula

C18H32N8O3S

Molecular Weight

440.56

References & Citations

[1]Denz C R, et al. Targeting the cell cycle with AZD8421, a potent and highly selective CDK2 inhibitor[J]. Cancer Research, 2024, 84 (6_Supplement) : 5730-5730.|[2]Kudo, R., et al., (2024) . Long-term breast cancer response to CDK4/6 inhibition defined by TP53-mediated geroconversion. Cancer cell, 42 (11), 1919–1935.e9.